Massachusetts Institute of Technology
Department of Biology Headquarters, Building 68-13
77 Massachusetts Avenue
Cambridge
Massachusetts
02139-4307
United States
Tel: 617-253-4701
Fax: 617-253-8699
Website: http://www.mit.edu/
Email: mitbiohq@mit.edu
About Massachusetts Institute of Technology
The mission of MIT is to advance knowledge and educate students in science, technology and other areas of scholarship that will best serve the nation and the world in the 21st century.The Institute is committed to generating, disseminating and preserving knowledge, and to working with others to bring this knowledge to bear on the world's great challenges. MIT is dedicated to providing its students with an education that combines rigorous academic study and the excitement of discovery with the support and intellectual stimulation of a diverse campus community. We seek to develop in each member of the MIT community the ability and passion to work wisely, creatively and effectively for the betterment of humankind.
Last Updated: 07-08-03
627 articles with Massachusetts Institute of Technology
-
Every year, the Breakthrough Prize Foundation awards a collective total of $22 million to nine researchers for achievements in the Life Sciences, Fundamental Physics and Mathematics.
-
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
-
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
10/3/2018
Patent agreement covers rights to develop combination therapies and identified predictive clinical biomarker across cancer types, expanding indications for Onvansertib
-
Watertown, Massachusetts-based Lyra Therapeutics closed a Series B financing worth $29.5 million. Its lead compound is LYR-210, which the company plans to take into a Phase II clinical trial for chronic rhinosinusitis
-
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
-
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
-
RootPath, headquartered in Cambridge, Massachusetts, announced a $7 million seed funding round. The financing was led by Sequoia China. Volcanics Venture, BV (Baidu Ventures) and NestBio Ventures participated.
-
Merus Announces Formation of a Scientific Advisory Board
8/22/2018
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals.
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
-
Watertown, Massachusetts-based SQZ Biotechnologies completed an oversubscribed Series C financing worth $72 million. New investors included Everblue, Illumina Ventures, Invus, Orient Life, and Viva Ventures Biotech Group.
-
IGM Biosciences, a privately-held biotech company located in Mountain View, California, announced that Daniel S. Chen will be the company’s new chief medical officer. Chen arrives from Genentech/Roche, where he was most recently vice president, Global Head of Cancer Immunotherapy.
-
July 13 Research Roundup: Gene Therapy for Cholesterol, Beta-Thalassemia, and Kidney Disease, and...
7/13/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them from gene therapy for cholesterol to kidney disease and more. -
Charles River Adds ERS License to CRISPR/Cas9 Service Offering
12/6/2017
The license, coupled with the existing license through the Broad Institute of MIT and Harvard, allows Charles River to offer custom in vivo and in vitro genome editing.
-
Syngenta Obtains Non-Exclusive IP License From Broad Institute for CRISPR-Cas9 Genome-Editing Technology for Agriculture Applications
11/2/2017
CRISPR-Cas9 genome editing technology complements Syngenta’s already robust plant breeding innovation toolbox
-
Designing Smart Tattoos To Help Monitor Your Health, MIT Study Reveals
10/3/2017
-
New Test Rapidly Diagnoses Zika, MIT Study Reveals
9/28/2017
-
Meet the Biotech That Just Got Seed Funding From MIT's New $170 Million Venture Fund
9/19/2017
-
Blood Testing Via Sound Waves May Replace Some Tissue Biopsies, MIT Reveals
9/19/2017
-
Institut Marquès Presents Their Studies On Music And The Beginning Of Life At The MIT
9/18/2017
-
There's A $100 Million Plan To End Paralysis With A Synthetic Spinal Cord, MIT Reveals
9/14/2017